MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
MiniMed reported Q1 FY27 net sales of $843 million, up 16.6% year-over-year, driven by accelerating U.S. growth and robust international demand. Management raised full-year organic revenue growth guidance to approximately 10.5%, up from prior guidance of 10%, citing strong execution across its innovation pipeline. Key operational highlights included the U.S.
Key figures
- Revenue
- 843000000
- Guidance
- FY27 organic revenue growth ~10.5%, raised from ~10%; Adjusted EBITDA margin ~16%, reaffirmed
- Revenue Yoy
- 16.6%
- Cgm revenue
- 431000000
- Us net sales
- 240000000
- Pumps revenue
- 144000000
- Consumables revenue
- 261000000
- Us net sales growth
- 13.1%
- Organic revenue growth
- 15.8%
- International net sales
- 603000000
- International net sales growth
- 18.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.